

A photograph showing three people in a laboratory setting. An older man with grey hair and glasses, wearing a dark suit and blue tie, is pointing at a computer monitor. A woman with dark hair, wearing a white lab coat, is also pointing at the monitor. A younger man in a white lab coat stands behind them, looking at the screen. The monitor displays a colorful, abstract image, possibly a microscopic view of cells. The background shows laboratory equipment and shelves.

Creating a Breakthrough Living Drug

Providence Cancer Institute is a leading force in the global effort to finish cancer. A three-decade long commitment to advancements in immunotherapy research are making world-class treatment and care available to patients in Oregon and across the country.

The Earle A. Chiles Research Institute, a division of Providence Cancer Institute, is home to industry-leading scientific and clinical researchers. Together they develop novel immunotherapies, enhance the global understanding of the basic biology of cancer, and translate those findings into effective new treatments for patients.

Patients from all over the world are treated at the Robert W. Franz Cancer Center. Many have exhausted other treatment options and come to participate in one of 150 open trials—five times more clinical trial offerings than the national average.


Groundbreaking new discovery

Providence Cancer Institute is no stranger to scientific breakthroughs. We led the world's first successful immunotherapy clinical trial for metastatic melanoma and the world's first clinical trial using anti-OX40 for patients with newly diagnosed head and neck cancers.

We are also the first research center in Oregon for adoptive cellular therapy – a highly personalized type of cancer immunotherapy. In a clinical trial led by Eric Tran, Ph.D., and Rom Leidner, M.D., we pioneered genetically engineered T cell transfer therapy, a new form of adoptive cellular therapy that genetically alters T cells in a laboratory to express the proper receptor so they can find and destroy cancer cells more effectively.

"The fact that a single infusion of reprogrammed T cells could cause metastatic pancreatic tumors to shrink makes me optimistic that we are on the right track. Now we have to make this therapy more potent and work for more patients."

Eric Tran, Ph.D.,
associate member,
Adoptive Cell Therapy Lab



Groundbreaking new discovery (continued)

In June 2022, Drs. Tran and Leidner reported the world's first case of metastatic pancreatic cancer regression following the administration of genetically engineered T cells. **We now know that we can change the way the world treats cancer.**

The promise of adoptive cellular therapy has led us to establish a landmark phase 1 clinical trial called, the HOTSPOT TCR-T trial. We believe this leading-edge treatment can be effective against colon, pancreatic, lung and other common solid cancers which account for 85% of annual cancer deaths.

Providence Cancer Institute's unique combination of size, grit and expertise makes us one of the few centers globally that can successfully lead this effort.

"We are at the doorstep of what may be a breakthrough 'living drug.' There is no better place than the Earle A. Chiles Research Institute for the visionary and indefatigable commitment needed to develop this kind of groundbreaking cancer treatment."

Rom Leidner, M.D.,
associate member,
Adoptive Cell Therapy Lab



Your opportunity for impact

Generous supporters drive innovation at Providence Cancer Institute. More than 70% of research is funded by philanthropy, powered by a community of grateful patients, family members and friends. Your gift will propel our efforts to finish cancer.

We are seeking gifts and pledges at all levels to finish the first 24-patient HOTSPOT TCR-T trial and seed a second phase clinical trial. Patients with late-stage cancer will be given hope and an opportunity to become pioneers in this first-in-human treatment.

For more information on how you can become involved in supporting this critical work, please contact:

Jon Mohr | Director of Development

Providence Portland Medical Foundation
Providence Cancer Institute
4805 NE Glisan St., Suite 1G14 | Portland, OR 97213
970-412-5022 | Lawrence.Mohr@Providence.org
ProvidenceFoundations.org/cancer



Inspiring Generosity ♥

OUR MISSION

As expressions of God's healing love, witnessed through the ministry of Jesus, we are steadfast in serving all, especially those who are poor and vulnerable.

OUR VALUES

Compassion, Dignity, Justice,
Excellence, Integrity